{"filing":{"accession_number":"0001193125-26-338097","cik":"0001810560","ticker":"REVBW","company_name":"REVELATION BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"revb-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-20260806.htm"},"events":[{"id":25648,"run_id":23277,"accession_number":"0001193125-26-338097","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a straightforward earnings release disclosing financial results for the three and six months ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents consolidated statements of operations and balance sheets, net loss figures ($3.3M and $6.3M respectively), cash position ($11.5M), and operational highlights including clinical trial progress. The disclosure is material to investors assessing the company's financial condition and runway.","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26534,"accession_number":"0001193125-26-338097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing financial results for the three and six months ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents consolidated statements of operations and balance sheets, net loss figures ($3.3M and $6.3M respectively), cash position ($11.5M), and operational highlights including clinical trial progress. The disclosure is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:53.738441+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26534,"accession_number":"0001193125-26-338097","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a straightforward earnings release disclosing financial results for the three and six months ended June 30, 2026. The press release, furnished as Exhibit 99.1, presents consolidated statements of operations and balance sheets, net loss figures ($3.3M and $6.3M respectively), cash position ($11.5M), and operational highlights including clinical trial progress. The disclosure is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:53.738441+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-08-06"}]}